Sign in Subscribe
Class action lawsuits

Securities Lawsuit Filed Against Sarepta Therapeutics and Executives

Strategic Insights

— 2 min read

A securities lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the company's senior executives for potential violations of the federal securities laws. The lawsuit alleges that the company repeatedly touted the safety profile of its therapy, Elevidys, which is used to treat Duchenne muscular dystrophy, despite knowing that it causes fatal acute liver failure in some patients. This alleged deception led to a significant decline in the company's stock price.

Key Takeaways:

  • Sarepta Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases, with its most important product being Elevidys, a therapy for the treatment of Duchenne muscular dystrophy.
  • The lawsuit alleges that Sarepta repeatedly touted the safety profile of Elevidys and told investors that the benefits of the treatment outweighed its risks, despite knowing that the treatment causes fatal acute liver failure in some patients.
  • The stock price of Sarepta fell significantly after the company announced that several patients had died from acute liver failure while taking Elevidys.
  • The lawsuit claims that investors who purchased Sarepta securities between May 2019 and July 2025 may have been able to recover damages.
  • The case is pending in the U.S. District Court for the Southern District of New York and is captioned Dolgicer v. Sarepta Therapeutics, Inc., et al.
  • Bleichmar Fonti & Auld LLP, a leading international law firm representing plaintiffs in securities class actions and shareholder litigation, is handling the case.
  • The firm has a history of successfully representing clients in high-profile cases, including recovering over $900 million in value from Tesla, Inc.'s Board of Directors and $420 million from Teva Pharmaceutical Ind. Ltd.

Statistics:

  • $27.81 per share represents the decline in Sarepta stock price on March 18, 2025, after the company announced that a patient had died from acute liver failure.
  • $73.54 per share represents the price of Sarepta stock on March 18, 2025.
  • 27% represents the percentage decline in Sarepta stock price on March 18, 2025.
  • $15.24 per share represents the decline in Sarepta stock price on June 16, 2025.
  • 42% represents the percentage decline in Sarepta stock price on June 16, 2025.
  • $20.94 per share represents the price of Sarepta stock on June 16, 2025.
  • 40% represents the decline in Sarepta stock price on July 18, 2025.

Sources:

  • GlobeNewswire
  • Dolgicer v. Sarepta Therapeutics, Inc., et al.
  • Bleichmar Fonti & Auld LLP
  • Chambers USA
  • The Legal 500
  • ISS SCAS
  • National Law Journal
  • Lawdragon
  • Law360
  • Thomson Reuters

Read more